Capacity Building for Clinical Trials in Sickle Cell Disease (SCD) – Education for Healthcare Professionals
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: Mar 11, 2026
Geographic Scope: United States
Clinical Area: Sickle Cell Disease
Application Due Date: May 5, 2026
Specific Area of Interest: Potential applicants are encouraged to provide educational programs focusing on preparing multidisciplinary staff including: physicians, Advanced Practice Providers (APPs), nurses, research coordinators, and pharmacists to participate confidently in SCD clinical trials through targeted training in SCD research, good clinical practice, regulatory requirements, and culturally responsive research engagement.
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.